Want to see CRBP full AI Analyst Report?
CRBP Stock Chart & Stats
$11.31
-$0.15(-1.61%)
At close: 4:00 PM EDT
$11.31
-$0.15(-1.61%)
Day’s Range― - ―
52-Week Range$4.22 - $20.00
Previous CloseN/A
Volume172.71K
Average Volume (3M)1.25M
Market Cap
$86.26M
Enterprise Value$68.37M
Total Cash (Recent Filing)$117.94M
Total Debt (Recent Filing)$4.26M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 10, 2026EPS Estimate
-1.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.19
Shares Outstanding19,341,293
10 Day Avg. Volume1,012,195
30 Day Avg. Volume1,254,619
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.40K
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$36.67Price Target Upside224.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.43
Revenue Forecast (FY)$1.67M
Bulls Say, Bears Say
Bulls Say
Clinical Progress In OncologyCRB-701 has generated meaningful early efficacy data and progressed into a registrational study, improving the company’s clinical maturity. Successful execution could create a path toward a major oncology product, while the pembrolizumab combination expands the program’s strategic potential.
Obesity Pipeline OptionalityCRB-913 adds a potentially differentiated obesity opportunity beyond Corbus’s oncology focus. Its reported weight loss, tolerability, and lower gastrointestinal event rates versus leading oral GLP-1 reports support further development and could broaden the company’s future pipeline value.
Liquidity And Funding RunwayThe stated liquidity runway gives Corbus time to advance multiple clinical programs without an immediately stated financing need. This supports execution of registrational and Phase 2 work, allowing upcoming clinical milestones to develop before additional capital decisions become necessary.
Bears Say
Pre-Revenue Business ModelWith no recurring product revenue, Corbus lacks an operating base that can internally fund research and development. Its value therefore depends heavily on clinical progress and eventual commercialization, making financial performance less predictable than that of an established drug company.
Widening Losses And Cash BurnLosses and cash consumption have accelerated materially, increasing the capital required to sustain Corbus’s development programs. Persistent negative operating and free cash flow can constrain strategic flexibility and raise the importance of maintaining sufficient funding through later-stage trials.
Reliance On External FinancingDependence on external financing is a structural weakness for a company without recurring product sales. Continued development may require additional capital before commercial revenues emerge, leaving Corbus reliant on financing transactions and the ability to secure funding on acceptable terms.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.22 and its highest was $20.00 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $86.26M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 19 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.259 by -$0.551.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.21.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 19,341,293 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.259. Following the earnings report the stock price went up 1.776%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.67 (224.20% Upside)
$36.67 (224.20% Upside)
Blogger Sentiment
Bullish
CRBP Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 39.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.82%
12-Months-Change
Fundamentals
Return on Equity
-87.05%
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
CRBP Stock 12 Month Forecast
Average Price Target
$36.67
▲(224.20% Upside)
Technical Analysis
Ownership Overview
15.08% Insiders
5.07% Mutual Funds
0.39% Other Institutional Investors
69.44% Public Companies and
Individual Investors